I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Home > News and Publications > JHM Publications > Psychiatry Newsletter > Hopkins Brain Wise Summer 2010
Psychiatry Newsletter - You'll Get No Kick From Cocaine
Hopkins Brain Wise Summer 2010
You'll Get No Kick From Cocaine
Date: July 10, 2010
Addictions researchers Andrew Tompkins and Maxine Stitzer see vaccines’ potential as part of a wave of change in addictions treatment. “There’s no magic bullet,” says Stitzer, but patients could go longer between visits and the biology is more strongly on their side.
What if there were a safe and lasting way to block the high that users get from cocaine, no matter what form—injected, snorted, or even the potent inhaled drug called crack?
That possibility comes a little closer this summer, when Hopkins begins trials of a prototype cocaine vaccine on 50 men and women who actively use the drug but insist just as actively that they want to quit.
Some 300 will participate nationwide.
Stopping cocaine’s effects completely could bring a sea change in recovery strategies, the researchers say. But even if the vaccine merely blunts the high, that might tip the balance enough to make existing tactics more effective. The potential is there; it’s just waiting to be realized.
Led by Maxine Stitzer, Ph.D., and Andrew Tompkins, M.D., with the Behavioral Pharmacology Research Unit, the Hopkins team is one of six nationally to conduct phase II trials of the TA-CD vaccine. Ideally, the vaccinations will prompt subjects’ immune systems to create useful antibodies—those able to pick off cocaine molecules before they cross the blood-brain barrier to stimulate dopamine-based reward circuits in the brain.
The upcoming studies follow a decade of animal research and then a sentinel inpatient vaccine study of cocaine-users. “Even before it appeared in a journal last fall, the results of that inpatient trial caused a stir in the research community,” says Stitzer. “It was the first time that a treatment substantially reduced the subjective effects of cocaine. After literally years of seeing negative trials, this would be hard to overlook.
“That said,” she adds, “we know there are still challenges.” The anti-cocaine antibody levels, for example, fade within a year, making booster shots necessary. In a larger outpatient study, just half of fully inoculated people produced enough antibodies to dull cocaine’s effects. Still, Tompkins points out, the possibility of helping even that many motivated cocaine users is highly significant for a life-sinking illness that affects millions.
He also takes heart in the potency of the vaccine for those who are affected by it. “It appears to damp down even crack cocaine,” Tompkins says, “which travels the fastest to the brain.”
“It’s time for a new approach,” says Stitzer. Unlike other addictive drugs, cocaine has danced away from 30 years of concerted searching for a medication to stop dependence. The same is true for its amphetamine cousins and the other stimulants. There’s no methadone-equivalent, as exists for heroin or other opioid addictions. Much of the problem, Tompkins says, stems from the stimulants’ intimacy with normal brain circuitry: “That makes it difficult to find an agent that blocks the drugs while leaving important brain function intact.”
For the upcoming trials, it will take several injections of vaccine to get the anti-cocaine antibody titer as high as necessary. So five injections are scheduled at intervals, as is antibody sampling. The physiology and safety will still be under study, but researchers’ eyes will linger longest on the urine tests and written surveys that would flag a hoped-for drop in subjects’ cocaine use.
If the trials are successful, says Stitzer, the vaccine would then be a candidate for FDA approval, and then, ideally, tailored to community use.
For information: 410-550-5044